{"event":"longevity-tracker","title":"Longevity research tracker: aging biology milestones","state":"developing","updated":"2026-10-10T00:00:00.000Z","entries":[{"id":"1byqmjq","at":"2026-10-08T00:00:00.000Z","title":"First-in-human ER-100 data: no serious adverse events in three patients","status":"reported","body":"Company-reported data from an ongoing safety study; visual-field changes are preliminary.","cites":[{"id":"longevity-er100-fih-safety","n":1,"url":"https://www.manilatimes.net/2026/10/09/tmt-newswire/globenewswire/life-biosciences-announces-first-in-human-data-from-ongoing-phase-1-trial-evaluating-er-100-in-optic-neuropathies/2442195","publisher":"Life Biosciences (GlobeNewswire release)","short":"Life Biosciences"},{"id":"longevity-er100-fih-visual-fields","n":44,"url":"https://www.manilatimes.net/2026/10/09/tmt-newswire/globenewswire/life-biosciences-announces-first-in-human-data-from-ongoing-phase-1-trial-evaluating-er-100-in-optic-neuropathies/2442195","publisher":"Life Biosciences (GlobeNewswire release)","short":"Life Biosciences"},{"id":"longevity-er100-dose-escalation","n":21,"url":"https://www.manilatimes.net/2026/10/09/tmt-newswire/globenewswire/life-biosciences-announces-first-in-human-data-from-ongoing-phase-1-trial-evaluating-er-100-in-optic-neuropathies/2442195","publisher":"Life Biosciences (GlobeNewswire release)","short":"Life Biosciences"}]},{"id":"1wdu1r3","at":"2026-09-16T00:00:00.000Z","title":"Loyal says FDA accepted effectiveness section for big-dog drug LOY-003","status":"reported","body":"Loyal's third RXE acceptance, after LOY-001 (2023) and LOY-002 (2025).","cites":[{"id":"longevity-loy003-rxe","n":8,"url":"https://loyal.com/posts/loy-003-rxe","publisher":"Loyal","short":"Loyal"}]},{"id":"10pzut8","at":"2026-08-11T00:00:00.000Z","title":"XPRIZE Healthspan names 20 finalists","status":"confirmed","cites":[{"id":"longevity-xprize-finalists","n":43,"url":"https://www.xprize.org/prizes/healthspan","publisher":"XPRIZE Foundation","short":"XPRIZE Foundation"}]},{"id":"vpsjy8","at":"2026-06-23T00:00:00.000Z","title":"Calico's fosigotifator gets Breakthrough Therapy Designation","status":"confirmed","body":"For vanishing white matter disease, not aging.","cites":[{"id":"longevity-calico-fosigotifator","n":13,"url":"https://www.calicolabs.com/press/calico-life-sciences-announces-fosigotifator-granted-breakthrough-therapy-designation-by-the-u-s-fda-for-the-treatment-of-vanishing-white-matter-disease/","publisher":"Calico Life Sciences","short":"Calico Life Sciences"}]},{"id":"m9vk5t","at":"2026-06-09T00:00:00.000Z","title":"First patient dosed with ER-100","status":"confirmed","cites":[{"id":"longevity-er100-first-dose","n":27,"url":"https://www.biospace.com/press-releases/life-biosciences-announces-first-patient-dosed-in-phase-1-trial-of-er-100-for-optic-neuropathies","publisher":"Life Biosciences (press release via BioSpace)","short":"Life Biosciences"}]},{"id":"hp49hn","at":"2026-05-08T00:00:00.000Z","title":"Cell study builds multimodal and protein-based aging clocks","status":"confirmed","cites":[{"id":"longevity-multimodal-clocks-2026","n":18,"url":"https://pubmed.ncbi.nlm.nih.gov/42105758/","publisher":"Cell (Cell Press)","short":"Cell"}]},{"id":"w0etap","at":"2026-04-08T00:00:00.000Z","title":"Life Biosciences announces $80 million Series D","status":"confirmed","cites":[{"id":"longevity-lifebio-series-d","n":42,"url":"https://www.lifebiosciences.com/news/press-releases/","publisher":"Life Biosciences","short":"Life Biosciences"}]},{"id":"196fxba","at":"2026-01-28T00:00:00.000Z","title":"FDA clears first partial reprogramming trial (ER-100)","status":"confirmed","cites":[{"id":"longevity-er100-ind","n":7,"url":"https://www.lifebiosciences.com/news/press-releases/","publisher":"Life Biosciences","short":"Life Biosciences"}]},{"id":"qunn9v","at":"2026-01-13T00:00:00.000Z","title":"FDA accepts safety section for LOY-002","status":"confirmed","cites":[{"id":"longevity-loy002-tas","n":41,"url":"https://www.dvm360.com/view/lifespan-extension-drug-in-development-for-senior-dogs-reaches-a-new-milestone","publisher":"dvm360","short":"dvm360"}]},{"id":"10pmzdz","at":"2025-11-05T00:00:00.000Z","title":"Calico's kidney antibody ABBV-CLS-628 gets Orphan Drug Designation","status":"confirmed","cites":[{"id":"longevity-calico-adpkd","n":40,"url":"https://www.calicolabs.com/press/calico-life-sciences-announces-u-s-fda-orphan-drug-designation-for-investigational-treatment-of-autosomal-dominant-polycystic-kidney-disease/","publisher":"Calico Life Sciences","short":"Calico Life Sciences"}]},{"id":"1ekezuc","at":"2025-09-18T00:00:00.000Z","title":"Unity Biotechnology stockholders approve dissolution","status":"confirmed","body":"The senolytic developer had cut all staff in May 2025 after its ASPIRE eye-disease data.","cites":[{"id":"longevity-unity-dissolution","n":12,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000114036125030046/ny20051823x2_def14a.htm","publisher":"Unity Biotechnology (SEC filing)","short":"Unity Biotechnology"}]},{"id":"1aw4ca1","at":"2025-08-14T00:00:00.000Z","title":"Altos Labs scientists link partial reprogramming to reversing 'mesenchymal drift'","status":"confirmed","cites":[{"id":"longevity-mesenchymal-drift","n":38,"url":"https://pubmed.ncbi.nlm.nih.gov/40816266/","publisher":"Cell (Cell Press)","short":"Cell"},{"id":"longevity-altos-mesenchymal-drift-affiliation","n":39,"url":"https://pubmed.ncbi.nlm.nih.gov/40816266/","publisher":"Cell (Cell Press)","short":"Cell"}]},{"id":"8i0pld","at":"2025-07-24T00:00:00.000Z","title":"Two-decade ITP review finds most lifespan drugs work mainly in males","status":"confirmed","cites":[{"id":"longevity-itp-sex-differences","n":36,"url":"https://pubmed.ncbi.nlm.nih.gov/40717358/","publisher":"Journals of Gerontology, Series A","short":"Journals of Gerontology"},{"id":"longevity-itp-scale","n":37,"url":"https://pubmed.ncbi.nlm.nih.gov/40717358/","publisher":"Journals of Gerontology, Series A","short":"Journals of Gerontology"}]},{"id":"1ptr0mp","at":"2025-06-26T00:00:00.000Z","title":"Calico licenses IL-11 antibodies from Mabwell","status":"confirmed","cites":[{"id":"longevity-calico-mabwell-il11","n":35,"url":"https://www.calicolabs.com/press/mabwell-bioscience-and-calico-life-sciences-announce-exclusive-licensing-agreement-for-novel-il-11-targeting-monoclonal-antibody/","publisher":"Calico Life Sciences","short":"Calico Life Sciences"}]},{"id":"xve4b1","at":"2025-05-12T00:00:00.000Z","title":"XPRIZE Healthspan awards first milestone prizes","status":"confirmed","cites":[{"id":"longevity-xprize-first-milestone","n":34,"url":"https://www.xprize.org/prizes/healthspan","publisher":"XPRIZE Foundation","short":"XPRIZE Foundation"}]},{"id":"1v5jrjr","at":"2025-04-22T00:00:00.000Z","title":"Senolytic UBX1325 eye trial shows non-significant trend","status":"confirmed","cites":[{"id":"longevity-ubx1325-result","n":33,"url":"https://pubmed.ncbi.nlm.nih.gov/40261111/","publisher":"NEJM Evidence","short":"NEJM Evidence"}]},{"id":"1txfupl","at":"2025-04-04T00:00:00.000Z","title":"PEARL rapamycin trial: safe over 48 weeks, primary outcome unchanged","status":"confirmed","cites":[{"id":"longevity-pearl-results","n":4,"url":"https://pubmed.ncbi.nlm.nih.gov/40188830/","publisher":"Aging (Albany NY)","short":"Aging"}]},{"id":"1dqpwc0","at":"2025-02-26T00:00:00.000Z","title":"FDA accepts effectiveness section for Loyal's LOY-002","status":"confirmed","cites":[{"id":"longevity-loy002-rxe","n":32,"url":"https://www.dvm360.com/view/second-drug-for-canine-healthy-lifespan-extension-receives-fda-support","publisher":"dvm360","short":"dvm360"}]},{"id":"1ejm10b","at":"2025-02-14T00:00:00.000Z","title":"Design of TRIAD rapamycin trial in pet dogs published","status":"confirmed","cites":[{"id":"longevity-triad-design","n":31,"url":"https://pubmed.ncbi.nlm.nih.gov/39951177/","publisher":"GeroScience","short":"GeroScience"}]},{"id":"p017ql","at":"2025-01-17T00:00:00.000Z","title":"OpenAI says GPT-4b micro, built with Retro Biosciences, improved two Yamanaka factors","status":"reported","body":"Preliminary company claims, not peer reviewed when announced.","cites":[{"id":"longevity-openai-retro-gpt4b","n":11,"url":"https://www.technologyreview.com/2025/01/17/1110086/openai-has-created-an-ai-model-for-longevity-science/","publisher":"MIT Technology Review","short":"MIT Technology Review"}]},{"id":"1vjl9ys","at":"2025-01-06T00:00:00.000Z","title":"Calico's fosigotifator misses primary endpoint in HEALEY ALS trial","status":"confirmed","cites":[{"id":"longevity-calico-healey-als","n":14,"url":"https://www.calicolabs.com/press/calico-statement-on-fosigotifator-in-healey-als-platform-trial/","publisher":"Calico Life Sciences","short":"Calico Life Sciences"}]},{"id":"11ocscf","at":"2024-12-03T00:00:00.000Z","title":"Survey shows aging researchers disagree on what aging is","status":"confirmed","cites":[{"id":"longevity-expert-disagreement","n":30,"url":"https://pubmed.ncbi.nlm.nih.gov/39660064/","publisher":"PNAS Nexus","short":"PNAS Nexus"}]},{"id":"1in7zio","at":"2024-07-17T00:00:00.000Z","title":"Blocking IL-11 extends mouse lifespan by about a quarter","status":"confirmed","cites":[{"id":"longevity-il11-mice","n":15,"url":"https://pubmed.ncbi.nlm.nih.gov/39020175/","publisher":"Nature","short":"Nature"}]},{"id":"1pkjx3q","at":"2024-07-02T00:00:00.000Z","title":"Phase 2 senolytic trial in postmenopausal women misses primary endpoint","status":"confirmed","cites":[{"id":"longevity-farr-primary-null","n":3,"url":"https://pubmed.ncbi.nlm.nih.gov/38956196/","publisher":"Nature Medicine","short":"Nature Medicine"},{"id":"longevity-farr-exploratory","n":29,"url":"https://pubmed.ncbi.nlm.nih.gov/38956196/","publisher":"Nature Medicine","short":"Nature Medicine"}]},{"id":"yq4tj2","at":"2024-04-17T00:00:00.000Z","title":"Reanalysis finds metformin and four other compounds extend survival in ITP mice","status":"confirmed","body":"Metformin's effect was seen in males only, and only with the Gehan test.","cites":[{"id":"longevity-itp-gehan-metformin","n":28,"url":"https://pubmed.ncbi.nlm.nih.gov/38630424/","publisher":"GeroScience","short":"GeroScience"}]},{"id":"14nxzrw","at":"2024-02-14T00:00:00.000Z","title":"Nature Medicine paper: no consensus on validating aging biomarkers","status":"confirmed","cites":[{"id":"longevity-biomarkers-surrogate-endpoints","n":20,"url":"https://pubmed.ncbi.nlm.nih.gov/38355974/","publisher":"Nature Medicine","short":"Nature Medicine"}]},{"id":"4wuv0h","at":"2024-02-01T00:00:00.000Z","title":"Whole-body OSK gene therapy extends remaining lifespan of old male mice","status":"confirmed","body":"A company-run study (Rejuvenate Bio) in males only.","cites":[{"id":"longevity-macip-2024-aav-osk","n":16,"url":"https://pubmed.ncbi.nlm.nih.gov/38381405/","publisher":"Cellular Reprogramming","short":"Cellular Reprogramming"}]},{"id":"ifdr1o","at":"2013-06-06T00:00:00.000Z","title":"Hallmarks of aging framework published in Cell","status":"confirmed","body":"Nine hallmarks proposed as common denominators of aging; expanded to twelve in 2023.","cites":[{"id":"longevity-hallmarks-2013-nine","n":6,"url":"https://pubmed.ncbi.nlm.nih.gov/23746838/","publisher":"Cell (Cell Press)","short":"Cell"}]}]}